Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Long-term stability and protection efficacy of the RBD-targeting COVID-19 mRNA vaccine in nonhuman primates.

Tytuł:
Long-term stability and protection efficacy of the RBD-targeting COVID-19 mRNA vaccine in nonhuman primates.
Autorzy:
Zhao H; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, 100071, Beijing, China.
Wang TC; Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun, 130122, China.
Li XF; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, 100071, Beijing, China.
Zhang NN; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, 100071, Beijing, China.; School of Medicine, Tsinghua University, 100084, Beijing, China.
Li L; Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun, 130122, China.
Zhou C; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, 100071, Beijing, China.
Deng YQ; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, 100071, Beijing, China.
Cao TS; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, 100071, Beijing, China.
Yang G; State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, 102206, Beijing, China.
Li RT; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, 100071, Beijing, China.
Huang YJ; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, 100071, Beijing, China.
Li YG; Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun, 130122, China.
Zhang YM; Shandong Normal University, Jinan, 250014, China.
Li FX; Shandong Normal University, Jinan, 250014, China.
Zhou YR; Suzhou Abogen Biosciences, Suzhou, 215123, China.
Jiang YH; Suzhou Abogen Biosciences, Suzhou, 215123, China.
Lu XS; Suzhou Abogen Biosciences, Suzhou, 215123, China.
Sun SH; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, 100071, Beijing, China.
Cheng ML; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, 100071, Beijing, China.
Gu KP; Suzhou Abogen Biosciences, Suzhou, 215123, China.
Zhang M; Suzhou Abogen Biosciences, Suzhou, 215123, China.
Ma QQ; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, 100071, Beijing, China.
Yang X; State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, 102206, Beijing, China.
Ying B; Suzhou Abogen Biosciences, Suzhou, 215123, China. .
Gao YW; Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun, 130122, China. .
Qin CF; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, 100071, Beijing, China. .; School of Medicine, Tsinghua University, 100084, Beijing, China. .; Research Unit of Discovery and Tracing of Natural Focus Diseases, Chinese Academy of Medical Sciences, 100071, Beijing, China. .
Źródło:
Signal transduction and targeted therapy [Signal Transduct Target Ther] 2021 Dec 24; Vol. 6 (1), pp. 438. Date of Electronic Publication: 2021 Dec 24.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Original Publication: [London] : Nature Publishing Group, [2016]-
MeSH Terms:
Immunogenicity, Vaccine*
COVID-19/*immunology
COVID-19 Vaccines/*pharmacology
SARS-CoV-2/*immunology
Spike Glycoprotein, Coronavirus/*immunology
mRNA Vaccines/*pharmacology
Animals ; Antibodies, Neutralizing/immunology ; Antibodies, Viral/immunology ; COVID-19/prevention & control ; COVID-19 Vaccines/immunology ; Chlorocebus aethiops ; Humans ; Macaca fascicularis ; Vero Cells ; mRNA Vaccines/immunology
References:
Lancet. 2021 Jun 19;397(10292):2331-2333. (PMID: 34090624)
Med (N Y). 2021 Aug 13;2(8):979-992.e8. (PMID: 34223401)
Cell Rep. 2018 Aug 28;24(9):2312-2328.e7. (PMID: 30157426)
Vaccine. 2019 May 31;37(25):3326-3334. (PMID: 31079849)
AIDS. 2018 Nov 13;32(17):2533-2545. (PMID: 30289805)
Nat Commun. 2021 Feb 24;12(1):1260. (PMID: 33627662)
Science. 2020 Dec 4;370(6521):1227-1230. (PMID: 33115920)
Nature. 2021 Apr;592(7853):283-289. (PMID: 33524990)
Lancet Respir Med. 2020 May;8(5):475-481. (PMID: 32105632)
Nature. 2021 May;593(7857):130-135. (PMID: 33684923)
Cell. 2020 Sep 3;182(5):1271-1283.e16. (PMID: 32795413)
Nature. 2020 Oct;586(7830):578-582. (PMID: 32731258)
N Engl J Med. 2020 Oct 15;383(16):1544-1555. (PMID: 32722908)
Nature. 2021 Feb;590(7845):320-325. (PMID: 33260195)
Cell. 2021 Aug 5;184(16):4203-4219.e32. (PMID: 34242577)
Science. 2020 Jul 3;369(6499):77-81. (PMID: 32376603)
Emerg Microbes Infect. 2021 Dec;10(1):342-355. (PMID: 33555988)
Nature. 2020 May;581(7809):465-469. (PMID: 32235945)
Immunity. 2020 Dec 15;53(6):1281-1295.e5. (PMID: 33296685)
Cell Discov. 2020 Sep 3;6:61. (PMID: 32901211)
Immunity. 2020 Oct 13;53(4):724-732.e7. (PMID: 32783919)
Lancet. 2017 Sep 23;390(10101):1511-1520. (PMID: 28754494)
N Engl J Med. 2021 May 13;384(19):1866-1868. (PMID: 33761203)
J Pharm Sci. 2021 Mar;110(3):997-1001. (PMID: 33321139)
Nature. 2020 Oct;586(7830):583-588. (PMID: 32731257)
Science. 2020 May 29;368(6494):1012-1015. (PMID: 32303590)
Nature. 2021 Jan;589(7843):491-492. (PMID: 33505041)
Nat Rev Immunol. 2020 Jun;20(6):339-341. (PMID: 32317716)
Mol Cancer. 2021 Feb 16;20(1):33. (PMID: 33593376)
JAMA. 2021 Mar 9;325(10):998-999. (PMID: 33566056)
Nature. 2020 Oct;586(7830):516-527. (PMID: 32967006)
Lancet. 2020 Feb 15;395(10223):497-506. (PMID: 31986264)
J Clin Invest. 2020 Sep 1;130(9):4694-4703. (PMID: 32463803)
Cell. 2021 Jun 24;184(13):3452-3466.e18. (PMID: 34139176)
Science. 2020 Mar 27;367(6485):1444-1448. (PMID: 32132184)
Cell Host Microbe. 2020 Mar 11;27(3):325-328. (PMID: 32035028)
Emerg Microbes Infect. 2020 Dec;9(1):680-686. (PMID: 32207377)
Cytokine. 2018 Mar;103:34-37. (PMID: 29324258)
Signal Transduct Target Ther. 2020 Oct 13;5(1):237. (PMID: 33051445)
Chest. 2020 Nov;158(5):e215-e219. (PMID: 32622819)
Grant Information:
82041044 National Natural Science Foundation of China (National Science Foundation of China)
Substance Nomenclature:
0 (Antibodies, Neutralizing)
0 (Antibodies, Viral)
0 (COVID-19 Vaccines)
0 (Spike Glycoprotein, Coronavirus)
0 (mRNA Vaccines)
Entry Date(s):
Date Created: 20211225 Date Completed: 20220104 Latest Revision: 20220104
Update Code:
20240104
PubMed Central ID:
PMC8703211
DOI:
10.1038/s41392-021-00861-4
PMID:
34952914
Czasopismo naukowe
Messenger RNA (mRNA) vaccine technology has shown its power in preventing the ongoing COVID-19 pandemic. Two mRNA vaccines targeting the full-length S protein of SARS-CoV-2 have been authorized for emergency use. Recently, we have developed a lipid nanoparticle-encapsulated mRNA (mRNA-LNP) encoding the receptor-binding domain (RBD) of SARS-CoV-2 (termed ARCoV), which confers complete protection in mouse model. Herein, we further characterized the protection efficacy of ARCoV in nonhuman primates and the long-term stability under normal refrigerator temperature. Intramuscular immunization of two doses of ARCoV elicited robust neutralizing antibodies as well as cellular response against SARS-CoV-2 in cynomolgus macaques. More importantly, ARCoV vaccination in macaques significantly protected animals from acute lung lesions caused by SARS-CoV-2, and viral replication in lungs and secretion in nasal swabs were completely cleared in all animals immunized with low or high doses of ARCoV. No evidence of antibody-dependent enhancement of infection was observed throughout the study. Finally, extensive stability assays showed that ARCoV can be stored at 2-8 °C for at least 6 months without decrease of immunogenicity. All these promising results strongly support the ongoing clinical trial.
(© 2022. The Author(s).)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies